This clinical trial studies the effect of fludeoxyglucose F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in diagnosing early treatment response in patients with genitourinary cancer. FDG PET/CT may help to determine if the treatment is effective in early treatment, so as to prevent patients from being exposed to unnecessary toxic treatment.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04020978.
PRIMARY OBJECTIVE:
I. To use parametric PET to assess early treatment response in targeted therapy of genitourinary cancer (GUC).
SECONDARY OBJECTIVES:
I. To determine whether the functional changes measured by parametric PET/CT at two weeks is correlated with anatomical size change measured by standard CT at two months.
II. To determine whether the early response assessment by parametric PET/CT at two-week is predictive of standard CT response assessment at two-month.
EXPLORATORY OBJECTIVE:
I. Inclusion of subjects of various race and/or ethnicity to ensure findings can be generalizable to the entire population and to gather information about differences by race and/or ethnicity.
OUTLINE:
Patients receive FDG intravenously (IV) and undergo PET/CT over 60 minutes at baseline and 2 weeks after first dose of targeted treatment.
After completion of study, patients are followed up for 1 year after initiating the targeted treatment.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationUniversity of California Davis Comprehensive Cancer Center
Principal InvestigatorGuobao Wang
